Lemaitre Dan
Known title: DirectorCIK: 0001478479
Associated companies
Transaction History
| GMED | ▲ Buy | Option Exercise | 1,097 | $71K | 11/22/2024 | View on chart |
| GMED | ▼ Sell | Open Market | 1,097 | $93K | 11/22/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 13,278 | $864K | 11/21/2024 | View on chart |
| GMED | ▼ Sell | Open Market | 13,278 | $1.1M | 11/21/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 17,500 | $766K | 5/10/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 17,500 | $932K | 5/10/2024 | View on chart |
| GMED | ▼ Sell | Open Market | 63,300 | $4.1M | 5/10/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 17,500 | $763K | 5/10/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 1,450 | $35K | 5/15/2023 | View on chart |
| GMED | ▲ Buy | Option Exercise | 10,500 | $253K | 5/15/2023 | View on chart |
| GMED | ▲ Buy | Option Exercise | 14,000 | $357K | 5/15/2023 | View on chart |
| GMED | ▲ Buy | Option Exercise | 17,500 | $460K | 5/15/2023 | View on chart |
| GMED | ▼ Sell | Open Market | 43,450 | $2.5M | 5/15/2023 | View on chart |
| GMED | ▲ Buy | Option Exercise | 5,550 | $133K | 2/9/2023 | View on chart |
| GMED | ▲ Buy | Option Exercise | 5,250 | $66K | 1/27/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85
RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.